Pulmonary hypertension (PH) is a deadly condition with limited treatment options. Early studies implicated hypoxia-inducible factors (HIFs) as contributing to the development of hypoxia-induced PH. Recently, the use of cells derived from patients and transgenic animals with cell-specific deletions for various parts of the HIF system has furthered our understanding of the mechanisms by which HIFs control pulmonary vascular tone and remodeling to promote PH. Additionally, identification of HIF inhibitors further allows assessment of the potential for targeting HIFs to prevent and/or reverse PH. In this review, recent findings exploring the role of HIFs as potential mediators and therapeutic targets for PH are discussed.
ASJC Scopus subject areas
- Physiology (medical)